Storm Warning: The Trial Disclosure Forecast for 2017

November 14, 2018

As seen in R&D - Posted Nov. 14, 2018 - Original Article

Jan. 5, 2017 | 2017 will be a challenging year marked by public scrutiny of disclosure practices by regulators, stakeholders, and watchdog organizations. Expanded regulations require a significantly broader range of data to be disclosed within ever tighter timelines. 


Francine Lane, director of product strategy, and Thomas Wicks, chief strategy officer, recommend that sponsors should consider the growing transparency expectations and shift their focus from mere legal compliance to the ethical obligation for broader transparency. 

Continued on R&D

Previous Article
As ClinicalTrials.gov Turns 10, Will We See Compliance Improve?
As ClinicalTrials.gov Turns 10, Will We See Compliance Improve?

No More Articles